BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis and prognosis of epilepsy.
Epilepsy is a serious neurological condition that impacts over 65M people around the world.
BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.
Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.
Neuronostics is a new company (founded 2018) developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.
Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.
We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.
Neuronostics are delighted to announce a new partnership with the Universities of Nottingham and Birmingham to enable an MRC funded PhD studentship entitled Epilepsy as a dynamic disease. This 3.5-year PhD award is offered... [Read More]
9 October 2020 We are delighted to have been awarded the Start Up award from Medilink UK: totally unexpected, and hugely appreciated! It’s a fantastic recognition of all our hard work over... [Read More]
25 September 2020 We’re looking to recruit two full stack developers to join us from January 2021. Across the two roles, one will focus on developing our BioEP platform and the algorithms... [Read More]